Aggressive Ductal Carcinoma More Likely in Older Individuals

This article originally appeared here.
Risk of More Aggressive Ductal Carcinoma in Situ Rises With Age
Risk of More Aggressive Ductal Carcinoma in Situ Rises With Age

(HealthDay News) -- Ductal carcinoma in situ (DCIS) is much more likely to be aggressive when discovered in older women, according to a report published online Oct. 27 in Radiology.

Stefanie Weigel, M.D., Ph.D., a researcher at University Hospital Muenster in Germany, and colleagues aimed to investigate the link between age at screening and detection rates of the different grades of DCIS. The investigators looked at the medical records of 733,905 women, aged 50 to 69, who were screened with digital mammography between 2005 and 2008. The team looked at DCIS rates for five-year age groups, determining the rate per 1,000 women. They then divided their findings into DCIS of low, intermediate, and high grades.

In all, the investigators found 989 DCIS diagnoses. Of those, 419 were high-grade, 388 were intermediate-grade, and 182 were low-grade. The older the woman, the more likely she was to have a DCIS found, mostly due to an increase in intermediate- or high-grade DCIS. In the group aged 50 to 54, just 1.2 percent had a DCIS finding. By ages 65 to 69, 1.7 percent did.

What is new about this study is the finding about the grades, Weigel told HealthDay. That is important because the higher the grade, the more likely the progression to invasive cancer. "For the most aggressive type, high-grade DCIS, intervals between DCIS detection and the occurrence of invasive carcinoma have been described to be five years, on average," Weigel said.

Full Text

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs